Viatris Inc. (VTRS)
- Previous Close
11.55 - Open
11.55 - Bid 11.46 x 1100
- Ask 11.49 x 1100
- Day's Range
11.36 - 11.65 - 52 Week Range
8.74 - 13.62 - Volume
4,799,629 - Avg. Volume
8,847,574 - Market Cap (intraday)
13.621B - Beta (5Y Monthly) 1.15
- PE Ratio (TTM)
229.40 - EPS (TTM)
0.05 - Earnings Date May 6, 2024 - May 10, 2024
- Forward Dividend & Yield 0.48 (4.18%)
- Ex-Dividend Date Mar 8, 2024
- 1y Target Est
15.71
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
www.viatris.com38,000
Full Time Employees
December 31
Fiscal Year Ends
Sector
Recent News: VTRS
Performance Overview: VTRS
Trailing total returns as of 4/25/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: VTRS
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: VTRS
Valuation Measures
Market Cap
13.62B
Enterprise Value
30.81B
Trailing P/E
229.40
Forward P/E
4.16
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
0.90
Price/Book (mrq)
0.67
Enterprise Value/Revenue
2.00
Enterprise Value/EBITDA
8.76
Financial Highlights
Profitability and Income Statement
Profit Margin
0.35%
Return on Assets (ttm)
2.79%
Return on Equity (ttm)
0.26%
Revenue (ttm)
15.43B
Net Income Avi to Common (ttm)
54.7M
Diluted EPS (ttm)
0.05
Balance Sheet and Cash Flow
Total Cash (mrq)
1.18B
Total Debt/Equity (mrq)
89.76%
Levered Free Cash Flow (ttm)
1.1B
Research Analysis: VTRS
Company Insights: VTRS
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: VTRS
Analyst Report: Viatris Inc.
Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. Remaining 60% of sales is derived from its portfolio of legacy products which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.
RatingPrice TargetDaily – Vickers Top Buyers & Sellers for 03/18/2024
The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.
Analyst Report: Viatris Inc
Viatris Inc., based in Pennsylvania, is a specialty and generic drug company formed in 2020 through the combination of Pfizer's Upjohn business and Mylan N.V. The shares are a component of the S&P 500. The company has 37,000 employees. Viatris has scientific, manufacturing, distribution, and regulatory expertise, and serves patients in more than 165 countries and territories. The company's portfolio includes more than 1,400 approved molecules across a wide range of therapeutic areas, spanning both noncommunicable and infectious diseases. Its products include complex generic and branded medicines and over-the-counter consumer products. The company's near-term plans include integrating its businesses and deleveraging; this is expected to take three years. In the medium term, the company plans to achieve cost synergies (of up to $1 billion) and revenue synergies, to grow via M&A, and to return capital to shareholders through dividends and share repurchases. Financial goals include a revenue CAGR of approximately 3%, an adjusted EBITDA CAGR of 4%-5%, and an adjusted EPS CAGR in the mid-teens.
RatingPrice TargetMarket Digest: M, NTAP, NYT, BCE, RHHBY, BHF, UBER, ALC, VTRS
March 4, 2024 Monday Tee Up: Jobs, Powell, COST